Funding will provide continued investment in manufacturing operations, contribute to expanding capacity and sustainability of facilities producing vital anti-infectives. In addition, the credit facility will support Xellia’s efforts to combat AMR and ensure antibiotic stewardship and extend a regional, reliable supply of treatments where patients need them around the world.
Copenhagen, Denmark, 8 December 2022 - Xellia Pharmaceuticals (‘Xellia’ or the ‘Group’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, has secured long term financing of $430m to support its growth strategy.
The $430m funding is provided by Xellia’s existing banking partners, Danske Bank and Nordea, and will be used to continue Xellia’s investment in its manufacturing facilities. This will allow for capacity expansion and ensure the long-term sustainability of manufacturing of critical anti-infective therapies and differentiated critical care products at its facilities in Europe, the U.S. and Asia.
Securing the manufacture of Xellia’s portfolio of anti-infectives is a vital part of Xellia’s efforts to combat the growing challenge of antimicrobial resistance and will help support the Company’s responsible antibiotic stewardship goals. The funding is also important to ensuring access to these crucial medicines when patients are in need around the world, through Xellia’s reliable, regional supply.
Additionally, the proceeds will be used to continue Xellia’s investment in R&D and innovation in its core area of anti-infectives and will also further support the development of the Company’s Premix franchise, which focuses on the development of critical hospital medicines, provided in a room-temperature stable, ready-to-use form with the potential to improve safety, speed of use and reduce dosing errors.
Sustainability has long been at the forefront of Xellia’s values, and this latest funding comes with commitments to key ESG targets, developed with its investors to ensure that they can be delivered in a meaningful way. These targets will be measured and reported on annually, demonstrating Xellia’s commitment to its ESG responsibilities.
Carl-Åke Carlsson, CEO and President, Xellia Pharmaceuticals, commented:
“This financing enables Xellia to drive forward the development and innovation which keeps us at the forefront of anti-infective and critical care manufacturing and ensures a reliable supply of these vital medicines around the world.
“Through the funding, we are also emphasizing our commitment to our ESG goals, which we believe strongly in and have been delivering on for many years. We are now well positioned for our future growth, and we look forward to expanding manufacturing at our locations worldwide.”
For more information, please contact:
Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00
Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Rozi Morris / Manisha Kuttetira
Tel: +44 (0) 20 7457 2020
Email: xellia@instinctif.com